Assessment of antibody-targeted Cas9-EDV activity. HEK293T and CD19 EGFP HEK293T cells were mixed at an approximate ratio of 3:1 and treated with B2M -targeting Cas9-EDVs displaying various targeting molecule pseudotypes. Cas9-EDVs were concentrated 10 and cells were treated with 50 l Cas9-EDVs. Analysis was performed 7 days post treatment to assess B2M knockout in EGFP + (on-target) and EGFP - (bystander) cells by amplicon sequencing. n = 3 technical replicates were used in all experiments. Error bars, s.e.m.
